They've shown alot of potential revenue down the road, but we need to see some revenue now. The "phase 1" topicals are the low hanging fruit, since they are the easiest to make. They need to get that ramped up and for sale where customers can find it.
As far as speculative investors, the ABBIE stem cell stuff is interesting, but they need to not keep using the same boiler plate messaging from the patent in every PR. Explain how it's different than other technologies in the same space and how it can be monetized in plain language. Investors aren't physicians....
News 
Market Data 
Discover 
